US20050158249A1 - Aerodynamically light particles for pulmonary drug delivery - Google Patents

Aerodynamically light particles for pulmonary drug delivery Download PDF

Info

Publication number
US20050158249A1
US20050158249A1 US11/064,065 US6406505A US2005158249A1 US 20050158249 A1 US20050158249 A1 US 20050158249A1 US 6406505 A US6406505 A US 6406505A US 2005158249 A1 US2005158249 A1 US 2005158249A1
Authority
US
United States
Prior art keywords
particles
μm
aerodynamically light
method
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/064,065
Inventor
David Edwards
Giovanni Caponetti
Jeffrey Hrkach
Noah Lotan
Justin Hanes
Abdellaziz Ben-Jebria
Robert Langer
Original Assignee
Edwards David A.
Giovanni Caponetti
Hrkach Jeffrey S.
Noah Lotan
Justin Hanes
Abdellaziz Ben-Jebria
Langer Robert S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US65557096A priority Critical
Priority to US08/739,308 priority patent/US5874064A/en
Priority to US09/211,940 priority patent/US6136295A/en
Priority to US09/562,988 priority patent/US6399102B1/en
Priority to US10/027,212 priority patent/US6635283B2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27096992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050158249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/441,948 priority patent/US6942868B2/en
Application filed by Edwards David A., Giovanni Caponetti, Hrkach Jeffrey S., Noah Lotan, Justin Hanes, Abdellaziz Ben-Jebria, Langer Robert S. filed Critical Edwards David A.
Priority to US11/064,065 priority patent/US20050158249A1/en
Publication of US20050158249A1 publication Critical patent/US20050158249A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g/cm3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.

Description

    RELATED APPLICATION
  • This application is a continuation of U.S. patent application Ser. No. 10/441,948, filed May 20, 2003 which is a continuation of Ser. No. 10/027,212, filed Dec. 20, 2001 which is a continuation of co-pending U.S. patent application Ser. No. 09/562,988, filed May 1, 2000, which is a continuation of U.S. patent application Ser. No. 09/211,940, filed Dec. 15, 1998, now U.S. Pat. No. 6,136,295, which is a Divisional of U.S. application Ser. No. 08/739,308 filed on Oct. 29, 1996, now U.S. Pat. No. 5,874,064 which is a continuation-in-part of U.S. patent application Ser. No. 08/655,570, filed on May 24, 1996. The entire teachings of the above applications are incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • The present invention relates generally to biodegradable particles of low density and large size for drug delivery to the pulmonary system.
  • Biodegradable particles have been developed for the controlled-release and delivery of protein and peptide drugs. Langer, R., Science, 249: 1527-1533 (1990). Examples include the use of biodegradable particles for gene therapy (Mulligan, R. C. Science, 260: 926-932 (1993)) and for ‘single-shot’ immunization by vaccine delivery (Eldridge et al., Mol. Immunol., 28: 287-294 (1991)).
  • Aerosols for the delivery of therapeutic agents to the respiratory tract have been developed. Adjei, A. and Garren, J. Pharm. Res. 7, 565-569 (1990); and Zanen, P. and Lamm, J. -W. J. Int. J. Pharm. 114, 111-115 (1995). The respiratory tract encompasses the upper airways, including the oropharynx and larynx, followed by the lower airways, which include the trachea followed by bifurcations into the bronchi and bronchioli. The upper and lower airways are called the conducting airways. The terminal bronchioli then divide into respiratory bronchioli which then lead to the ultimate respiratory zone, the alveoli, or deep lung. Gonda, I. “Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract,” in Critical Reviews in Therapeutic Drug Carrier Systems 6:273-313, 1990. The deep lung, or alveoli, are the primary target of inhaled therapeutic aerosols for systemic drug delivery.
  • Inhaled aerosols have been used for the treatment of local lung disorders including asthma and cystic fibrosis (Anderson et al., Am. Rev. Respir. Dis., 140: 1317-1324 (1989)) and have potential for the systemic delivery of peptides and proteins as well (Patton and Platz, Advanced Drug Delivery Reviews, 8:179-196 (1992)). However, pulmonary drug delivery strategies present many difficulties for the delivery of macromolecules; these include protein denaturation during aerosolization, excessive loss of inhaled drug in the oropharyngeal cavity (often exceeding 80%), poor control over the site of deposition, irreproducibility of therapeutic results owing to variations in breathing patterns, the often too-rapid absorption of drug potentially resulting in local toxic effects, and phagocytosis by lung macrophages.
  • Considerable attention has been devoted to the design of therapeutic aerosol inhalers to improve the efficiency of inhalation therapies. Timsina et. al., Int. J. Pharm. 101, 1-13 (1995); and Tansey, I. P., Spray Technol. Market 4, 26-29 (1994). Attention has also been given to the design of dry powder aerosol surface texture, regarding particularly the need to avoid particle aggregation, a phenomenon which considerably diminishes the efficiency of inhalation therapies owing to particle aggregation. French, D. L., Edwards, D. A. and Niven, R. W., J. Aerosol Sci. 27, 769-783 (1996). Attention has not been given to the possibility of using large particle size (>5 μm) as a means to improve aerosolization efficiency, despite the fact that intraparticle adhesion diminishes with increasing particle size. French, D. L., Edwards, D. A. and Niven, R. W. J. Aerosol Sci. 27, 769-783 (1996). This is because particles of standard mass density (mass density near 1 g/cm3) and mean diameters >5 μm are known to deposit excessively in the upper airways or the inhaler device. Heyder, J. et al., J. Aerosol Sci., 17:811-825 (1986). For this reason, dry powder aerosols for inhalation therapy are generally produced with mean diameters primarily in the range of <5 μm. Ganderton, D., J. Biopharmaceutical Sciences 3:101-105 (1992); and Gonda, I. “Physico-Chemical Principles in Aerosol Delivery,” in Topics in Pharmaceutical Sciences 1991, Crommelin, D. J. and K. K. Midha, Eds., Medpharm Scientific Publishers, Stuttgart, pp. 95-115, 1992. Large “carrier” particles (containing no drug) have been co-delivered with therapeutic aerosols to aid in achieving efficient aerosolization among other possible benefits. French, D. L., Edwards, D. A. and Niven, R. W. J. Aerosol Sci. 27, 769-783 (1996).
  • Local and systemic inhalation therapies can often benefit from a relatively slow controlled release of the therapeutic agent. Gonda, I., “Physico-chemical principles in aerosol delivery,” in: Topics in Pharmaceutical Sciences 1991, D. J. A. Crommelin and K. K. Midha, Eds., Stuttgart: Medpharm. Scientific Publishers, pp. 95-117, (1992). Slow release from a therapeutic aerosol can prolong the residence of an administered drug in the airways or acini, and diminish the rate of drug appearance in the bloodstream. Also, patient compliance is increased by reducing the frequency of dosing. Langer, R., Science, 249:1527-1533 (1990); and Gonda, I. “Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract,” in Critical Reviews in Therapeutic Drug Carrier Systems 6:273-313, (1990).
  • The human lungs can remove or rapidly degrade hydrolytically cleavable deposited aerosols over periods ranging from minutes to hours. In the upper airways, ciliated epithelia contribute to the “mucociliary escalator” by which particles are swept from the airways toward the mouth. Pavia, D. “Lung Mucociliary Clearance,” in Aerosols and the Lung: Clinical and Experimental Aspects, Clarke, S. W. and Pavia, D., Eds., Butterworths, London, 1984. Anderson et al., Am. Rev. Respir. Dis., 140: 1317-1324 (1989). In the deep lungs, alveolar macrophages are capable of phagocytosing particles soon after their deposition. Warheit, M. B. and Hartsky, M. A., Microscopy Res. Tech. 26:412-422 (1993); Brain, J. D., “Physiology and Pathophysiology of Pulmonary Macrophages,” in The Reticuloendothelial System, S. M. Reichard and J. Filkins, Eds., Plenum, New York, pp. 315-327, 1985; Dorries, A. M. and Valberg, P. A., Am. Rev. Resp. Disease 146, 831-837 (1991); and Gehr, P. et al. Microscopy Res. and Tech., 26, 423-436 (1993). As the diameter of particles exceeds 3 μm, there is increasingly less phagocytosis by macrophages. Kawaguchi, H. et al., Biomaterials 7:61-66 (1986); Krenis, L. J. and Strauss, B., Proc. Soc. Exp. Med., 107:748-750 (1961); and Rudt, S. and Muller, R. H., J. Contr. Rel., 22:263-272 (1992). However, increasing the particle size also minimizes the probability of particles (possessing standard mass density) entering the airways and acini due to excessive deposition in the oropharyngeal or nasal regions. Heyder, J. et al., J. Aerosol Sci., 17: 811-825 (1986). An effective dry-powder inhalation therapy for both short and long term release of therapeutics, either for local or systemic delivery, requires a powder that displays minimum aggregation, as well as a means of avoiding or suspending the lung's natural clearance mechanisms until drugs have been effectively delivered.
  • There is a need for improved inhaled aerosols for pulmonary delivery of therapeutic agents. There is a need for the development of drug carriers which are capable of delivering the drug in an effective amount into the airways or the alveolar zone of the lung. There further is a need for the development of drug carriers for use as inhaled aerosols which are biodegradable and are capable of controlled release of drug within the airways or in the alveolar zone of the lung.
  • It is therefore an object of the present invention to provide improved carriers for the pulmonary delivery of therapeutic agents. It is a further object of the invention to provide inhaled aerosols which are effective carriers for delivery of therapeutic agents to the deep lung. It is another object of the invention to provide carriers for pulmonary delivery which avoid phagocytosis in the deep lung. It is a further object of the invention to provide carriers for pulmonary drug delivery which are capable of biodegrading and releasing the drug at a controlled rate.
  • SUMMARY OF THE INVENTION
  • Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material, have a tap density less than 0.4 g/cm3 and a mean diameter between 5 μm and 30 μm. In one embodiment, for example, at least 90% of the particles have a mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers, proteins, or other water-soluble materials. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid residue incorporated per molecule therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. Other examples include particles formed of water-soluble excipients, such as trehalose or lactose, or proteins, such as lysozyme or insulin. The aerodynamically light particles can be used for enhanced delivery of a therapeutic agent to the airways or the alveolar region of the lung. The particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of a wide variety of therapeutic agents. They optionally may be co-delivered with larger carrier particles, not carrying a therapeutic agent, which have for example a mean diameter ranging between about 50 μm and 100 μm.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph comparing total particle mass of aerodynamically light and non-light, control particles deposited on the nonrespirable and respirable stages of a cascade impactor following aerosolization.
  • FIG. 2 is a graph comparing total particle mass deposited in the trachea and after the carina (lungs) in rat lungs and upper airways following intratracheal aerosolization during forced ventilation of aerodynamically light PLAL-Lys particles and control, non-light PLA particles.
  • FIG. 3 is a graph comparing total particle recovery of aerodynamically light PLAL-Lys particles and control PLA particles in rat lungs and following bronchoalveolar lavage.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Aerodynamically light, biodegradable particles for improved delivery of therapeutic agents to the respiratory tract are provided. The particles can be used in one embodiment for controlled systemic or local drug delivery to the respiratory tract via aerosolization. In a preferred embodiment, the particles have a tap density less than about 0.4 g/cm3. Features of the particle which can contribute to low tap density include irregular surface texture and porous structure. Administration of the low density particles to the lung by aerosolization permits deep lung delivery of relatively large diameter therapeutic aerosols, for example, greater than 5 μm in mean diameter. A rough surface texture also can reduce particle agglomeration and provide a highly flowable powder, which is ideal for aerosolization via dry powder inhaler devices, leading to lower deposition in the mouth, throat and inhaler device.
  • Density and Size of Aerodynamically Light Particles
  • Particle Size
  • The mass mean diameter of the particles can be measured using a Coulter Counter. The aerodynamically light particles are preferably at least about 5 microns in diameter. The diameter of particles in a sample will range depending upon depending on factors such as particle composition and methods of synthesis. The distribution of size of particles in a sample can be selected to permit optimal deposition within targeted sites within the respiratory tract.
  • The aerodynamically light particles may be fabricated or separated, for example by filtration, to provide a particle sample with a preselected size distribution. For example, greater than 30%, 50%, 70%, or 80% of the particles in a sample can have a diameter within a selected range of at least 5 μm. The selected range within which a certain percentage of the particles must fall may be for example, between about 5 and 30 μm, or optionally between 5 and 15 μm. In one preferred embodiment, at least a portion of the particles have a diameter between about 9 and 11 μm. Optionally, the particle sample also can be fabricated wherein at least 90%, or optionally 95% or 99%, have a diameter within the selected range. The presence of the higher proportion of the aerodynamically light, larger diameter (at least about 5 μm) particles in the particle sample enhances the delivery of therapeutic or diagnostic agents incorporated therein to the deep lung.
  • In one embodiment, in the particle sample, the interquartile range may be 2 μm, with a mean diameter for example of 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0 or 13.5 μm. Thus, for example, at least 30%, 40%, 50% or 60% of the particles may have diameters within the selected range 5.5-7.5 μm, 6.0-8.0 μm, 6.5-8.5 μm, 7.0-9.0 μm, 7.5-9.5 μm, 8.0-10.0 μm, 8.5-10.5 μm, 9.0-11.0 μm, 9.5-11.5 μm, 10.0-12.0 μm, 10.5-12.5 μm, 11.0-13.0 μm, 11.5-13.5 μm, 12.0-14.0 μm, 12.5-14.5 μm or 13.0-15.0 μm. Preferably the said percentages of particles have diameters within a 1 μm range, for example, 6.0-7.0 μm, 10.0-11.0 μm or 13.0-14.0 μm.
  • The aerodynamically light particles incorporating a therapeutic drug, and having a tap density less than about 0.4 g/cm3, with mean diameters of at least about 5 μm, are more capable of escaping inertial and gravitational deposition in the oropharyngeal region, and are targeted to the airways or the deep lung. The use of larger particles (mean diameter at least about 5 μm) is advantageous since they are able to aerosolize more efficiently than smaller, non-light aerosol particles such as those currently used for inhalation therapies.
  • In comparison to smaller non-light particles, the larger (at least about 5 μm) aerodynamically light particles also can potentially more successfully avoid phagocytic engulfment by alveolar macrophages and clearance from the lungs, due to size exclusion of the particles from the phagocytes' cytosolic space. Phagocytosis of particles by alveolar macrophages diminishes precipitously as particle diameter increases beyond 3 μm. Kawaguchi, H. et al., Biomaterials 7: 61-66 (1986); Krenis, L. J. and Strauss, B., Proc. Soc. Exp. Med., 107:748-750 (1961); and Rudt, S. and Muller, R. H., J. Contr. Rel., 22: 263-272 (1992). For particles of statistically isotropic shape (on average, particles of the powder possess no distinguishable orientation), such as spheres with rough surfaces, the particle envelope volume is approximately equivalent to the volume of cytosolic space required within a macrophage for complete particle phagocytosis.
  • Aerodynamically light particles thus are capable of a longer term release of a therapeutic agent. Following inhalation, aerodynamically light biodegradable particles can deposit in the lungs (due to their relatively low tap density), and subsequently undergo slow degradation and drug release, without the majority of the particles being phagocytosed by alveolar macrophages. The drug can be delivered relatively slowly into the alveolar fluid, and at a controlled rate into the blood stream, minimizing possible toxic responses of exposed cells to an excessively high concentration of the drug. The aerodynamically light particles thus are highly suitable for inhalation therapies, particularly in controlled release applications. The preferred mean diameter for aerodynamically light particles for inhalation therapy is at least about 5 μm, for example between about 5 and 30 μm.
  • The particles may be fabricated with the appropriate material, surface roughness, diameter and tap density for localized delivery to selected regions of the respiratory tract such as the deep lung or upper airways. For example, higher density or larger particles may be used for upper airway delivery, or a mixture of different sized particles in a sample, provided with the same or different therapeutic agent may be administered to target different regions of the lung in one administration.
  • Particle Density and Deposition
  • The particles having a diameter of at least about 5 μm and incorporating a therapeutic or diagnostic agent preferably are aerodynamically light. As used herein, the phrase “aerodynamically light particles” refers to particles having a tap density less than about 0.4 g/cm3. The tap density of particles of a dry powder may be obtained using a GeoPyc™ (Micrometrics Instrument Corp., Norcross, Ga. 30093). Tap density is a standard measure of the envelope mass density. The envelope mass density of an isotropic particle is defined as the mass of the particle divided by the minimum sphere envelope volume within which it can be enclosed.
  • Inertial impaction and gravitational settling of aerosols are predominant deposition mechanisms in the airways and acini of the lungs during normal breathing conditions. Edwards, D. A., J. Aerosol Sci. 26:293-317 (1995). The importance of both deposition mechanisms increases in proportion to the mass of aerosols and not to particle (or envelope) volume. Since the site of aerosol deposition in the lungs is determined by the mass of the aerosol (at least for particles of mean aerodynamic diameter greater than approximately 1 μm), diminishing the tap density by increasing particle surface irregularities and particle porosity permits the delivery of larger particle envelope volumes into the lungs, all other physical parameters being equal.
  • The low tap density particles have a small aerodynamic diameter in comparison to the actual envelope sphere diameter. The aerodynamic diameter, daer, is related to the envelope sphere diameter, d (Gonda, I., “Physico-chemical principles in aerosol delivery,” in Topics in Pharmaceutical Sciences 1991 (eds. D. J. A. Crommelin and K. K. Midha), pp. 95-117, Stuttgart: Medpham Scientific Publishers, 1992) by the formula:
    daer=d{square root}{square root over (ρ)}
    where the envelope mass ρ is in units of g/cm3. Maximal deposition of monodisperse aerosol particles in the alveolar region of the human lung (˜60%) occurs for an aerodynamic diameter of approximately daer=3 μm, Heyder, J. et al., J. Aerosol Sci., 17: 811-825 (1986). Due to their small envelope mass density, the actual diameter d of aerodynamically light particles comprising a monodisperse inhaled powder that will exhibit maximum deep-lung deposition is:
    d=3/{square root}{square root over (ρ)} μm (where ρ<1 g/cm3);
    where d is always greater than 3 μm. For example, aerodynamically light particles that display an envelope mass density, ρ=0.1 g/cm3, will exhibit a maximum deposition for particles having envelope diameters as large as 9.5 μm. The increased particle size diminishes interparticle adhesion forces. Visser, J., Powder Technology, 58:1-10. Thus, large particle size increases efficiency of aerosolization to the deep lung for particles of low envelope mass density, in addition to contributing to lower phagocytic losses.
  • Particle Materials
  • In order to serve as efficient and safe drug carriers in drug delivery systems, the aerodynamically light particles preferably are biodegradable and biocompatible, and optionally are capable of biodegrading at a controlled rate for delivery of a drug. The particles can be made of any material which is capable of forming a particle having a tap density less than about 0.4 g/cm3. Both inorganic and organic materials can be used. For example, ceramics may be used. Other non-polymeric materials (e.g. fatty acids) may be used which are capable of forming aerodynamically light particles as defined herein. Different properties of the particle can contribute to the aerodynamic lightness including the composition forming the particle, and the presence of irregular surface structure or pores or cavities within the particle.
  • Polymeric Particles
  • The particles may be formed from any biocompatible, and preferably biodegradable polymer, copolymer, or blend, which is capable of forming particles having a tap density less than about 0.4 g/cm3.
  • Surface eroding polymers such as polyanhydrides may be used to form the aerodynamically light particles. For example, polyanhydrides such as poly[(p-carboxyphenoxy)-hexane anhydride] (PCPH) may be used. Biodegradable polyanhydrides are described, for example, in U.S. Pat. No. 4,857,311, the disclosure of which is incorporated herein by reference.
  • In another embodiment, bulk eroding polymers such as those based on polyesters including poly(hydroxy acids) can be used. For example, polyglycolic acid (PGA) or polylactic acid (PLA) or copolymers thereof may be used to form the aerodynamically light particles, wherein the polyester has incorporated therein a charged or functionalizable group such as an amino acid as described below.
  • Other polymers include polyamides, polycarbonates, polyalkylenes such as polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), poly vinyl compounds such as polyvinyl alcohols, polyvinyl ethers, and polyvinyl esters, polymers of acrylic and methacrylic acids, celluloses and other polysaccharides, and peptides or proteins, or copolymers or blends thereof which are capable of forming aerodynamically light particles with a tap density less than about 0.4 g/cm3. Polymers may be selected with or modified to have the appropriate stability and degradation rates in vivo for different controlled drug delivery applications.
  • Polyester Graft Copolymers
  • In one preferred embodiment, the aerodynamically light particles are formed from functionalized polyester graft copolymers, as described in Hrkach et al., Macromolecules, 28:4736-4739 (1995); and Hrkach et al., “Poly(L-Lactic acid-co-amino acid) Graft Copolymers: A Class of Functional Biodegradable Biomaterials” in Hydrogels and Biodegradable Polymers for Bioapplications, ACS Symposium Series No. 627, Raphael M. Ottenbrite et al., Eds., American Chemical Society, Chapter 8, pp. 93-101, 1996, the disclosures of which are incorporated herein by reference. The functionalized graft copolymers are copolymers of polyesters, such as poly(glycolic acid) or poly(lactic acid), and another polymer including functionalizable or ionizable groups, such as a poly(amino acid). In a preferred embodiment, comb-like graft copolymers are used which include a linear polyester backbone having amino acids incorporated therein, and poly(amino acid) side chains which extend from the amino acid residues in the polyester backbone. The polyesters may be polymers of α-hydroxy acids such as lactic acid, glycolic acid, hydroxybutyric acid and hydroxy valeric acid, or derivatives or combinations thereof. The inclusion of ionizable side chains, such as polylysine, in the polymer has been found to enable the formation of more aerodynamically light particles, using techniques for making microparticles known in the art, such as solvent evaporation. Other ionizable groups, such as amino or carboxyl groups, may be incorporated, covalently or noncovalently, into the polymer to enhance surface roughness and porosity. For example, polyalanine could be incorporated into the polymer.
  • An exemplary polyester graft copolymer, which may be used to form aerodynamically light polymeric particles is the graft copolymer, poly(lactic acid-co-lysine-graft-lysine) (PLAL-Lys), which has a polyester backbone consisting of poly(L-lactic acid-co- L-lysine) (PLAL), and grafted poly-lysine chains. PLAL-Lys is a comb-like graft copolymer having a backbone composition, for example, of 98 mol % lactic acid and 2 mol % lysine and poly(lysine) side chains extending from the lysine sites of the backbone.
  • PLAL-Lys may be synthesized as follows. First, the PLAL copolymer consisting of L-lactic acid units and approximately 1-2% N ε carbobenzoxy-L-lysine (Z-L-lysine) units is synthesized as described in Barrera et al., J. Am. Chem. Soc., 115:11010 (1993). Removal of the Z protecting groups of the randomly incorporated lysine groups in the polymer chain of PLAL yields the free ε-amine which can undergo further chemical modification. The use of the poly(lactic acid) copolymer is advantageous since it biodegrades into lactic acid and lysine, which can be processed by the body. The existing backbone lysine groups are used as initiating sites for the growth of poly(amino acid) side chains.
  • The lysine ε-amino groups of linear poly(L-lactic acid-co-L-lysine) copolymers initiate the ring opening polymerization of an amino acid N-ε carboxyanhydride (NCA) to produce poly(L-lactic acid-co-amino acid) comblike graft copolymers. In a preferred embodiment, NCAs are synthesized by reacting the appropriate amino acid with triphosgene. Daly et al., Tetrahedron Lett., 29:5859 (1988). The advantage of using triphosgene over phosgene gas is that it is a solid material, and therefore, safer and easier to handle. It also is soluble in THF and hexane so any excess is efficiently separated from the NCAs.
  • The ring opening polymerization of amino acid N-carboxyanhydrides (NCAs) is initiated by nucleophilic initiators such as amines, alcohols, and water. The primary amine initiated ring opening polymerization of NCAs allows good control over the degree of polymerization when the monomer to initiator ratio (M/I) is less than 150. Kricheldorf, H. R. in Models of Biopolymers by Ring-Opening Polymerization, Penczek, S., Ed., CRC Press, Boca Raton, 1990, Chapter 1; Kricheldorf, H. R. α-Aminoacid-N-Carboxy Anhydrides and Related Heterocycles, Springer-Verlag, Berlin, 1987; and Imanishi, Y. in Ring-Opening Polymerization, Ivin, K. J. and Saegusa, T., Eds., Elsevier, London, 1984, Volume 2, Chapter 8. Methods for using lysine ε-amino groups as polymeric initiators for NCA polymerizations are described in the art. Sela, M. et al., J. Am. Chem. Soc., 78: 746 (1956).
  • In the reaction of an amino acid NCA with PLAL, the nucleophilic primary ε-amino of the lysine side chain attacks C-5 of the NCA leading to ring opening and formation of the amino acid amide, along with the evolution of CO2. Propagation takes place via further attack of the amino group of the amino acid amides on subsequent NCA molecules. The degree of polymerization of the poly(amino acid) side chains, the corresponding amino acid content in the graft copolymers and their resulting physical and chemical characteristics can be controlled by changing the M/I ratio for the NCA polymerization—that is, changing the ratio of NCA to lysine ε-amino groups of pLAL. Thus, in the synthesis, the length of the poly(amino acid), such as poly(lysine), side chains and the total amino acid content in the polymer may be designed and synthesized for a particular application.
  • The poly(amino acid) side chains grafted onto or incorporated into the polyester backbone can include any amino acid, such as aspartic acid, alanine or lysine, or mixtures thereof. The functional groups present in the amino acid side chains, which can be chemically modified, include amino, carboxylic acid, thiol, guanido, imidazole and hydroxyl groups. As used herein, the term “amino acid” includes natural and synthetic amino acids and derivatives thereof. The polymers can be prepared with a range of amino acid side chain lengths, for example, about 10-100 or more amino acids, and with an overall amino acid content of, for example, 7-72% or more depending on the reaction conditions. The grafting of poly(amino acids) from the pLAL backbone may be conducted in a solvent such as dioxane, DMF, or CH2Cl2, or mixtures thereof. In a preferred embodiment, the reaction is conducted at room temperature for about 2-4 days in dioxane.
  • Alternatively, the aerodynamically light particles for pulmonary drug delivery may be formed from polymers or blends of polymers with different polyester/amino acid backbones and grafted amino acid side chains, For example, poly(lactic acid-co-lysine-graft-alanine-lysine) (PLAL-Ala-Lys), or a blend of PLAL-Lys with poly(lactic acid-co-glycolic acid-block-ethylene oxide) (PLGA-PEG) (PLAL-Lys-PLGA-PEG) may be used.
  • In the synthesis, the graft copolymers may be tailored to optimize different characteristics of the aerodynamically light particle including: i) interactions between the agent to be delivered and the copolymer to provide stabilization of the agent and retention of activity upon delivery; ii) rate of polymer degradation and, thereby, rate of drug release profiles; iii) surface characteristics and targeting capabilities via chemical modification; and iv) particle porosity.
  • Formation of Aerodynamically Light Polymeric Particles
  • Aerodynamically light polymeric particles may be prepared using single and double emulsion solvent evaporation, spray drying, solvent extraction and other methods well known to those of ordinary skill in the art. The aerodynamically light particles may be made, for example using methods for making microspheres or microcapsules known in the art.
  • Methods developed for making microspheres for drug delivery are described in the literature, for example, as described by Mathiowitz and Langer, J. Controlled Release 5,13-22 (1987); Mathiowitz, et al., Reactive Polymers 6, 275-283 (1987); and Mathiowitz, et al., J. Appl. Polymer Sci. 35, 755-774 (1988), the teachings of which are incorporated herein. The selection of the method depends on the polymer selection, the size, external morphology, and crystallinity that is desired, as described, for example, by Mathiowitz, et al., Scanning Microscopy 4, 329-340 (1990); Mathiowitz, et, al., J. Appl. Polymer Sci. 45, 125-134 (1992); and Benita, et al., J. Pharm. Sci. 73, 1721-1724 (1984), the teachings of which are incorporated herein.
  • In solvent evaporation, described for example, in Mathiowitz, et al., (1990), Benita, and U.S. Pat. No. 4,272,398 to Jaffe, the polymer is dissolved in a volatile organic solvent, such as methylene chloride. Several different polymer concentrations can be used, for example, between 0.05 and 0.20 g/ml. The drug, either in soluble form or dispersed as fine particles, is added to the polymer solution, and the mixture is suspended in an aqueous phase that contains a surface active agent such as poly(vinyl alcohol). The aqueous phase may be, for example, a concentration of 1% poly(vinyl alcohol) w/v in distilled water. The resulting emulsion is stirred until most of the organic solvent evaporates, leaving solid microspheres, which may be washed with water and dried overnight in a lyophilizer.
  • Microspheres with different sizes (1-1000 microns) and morphologies can be obtained by this method which is useful for relatively stable polymers such as polyesters and polystyrene. However, labile polymers such as polyanhydrides may degrade due to exposure to water. For these polymers, solvent removal may be preferred.
  • Solvent removal was primarily designed for use with polyanhydrides. In this method, the drug is dispersed or dissolved in a solution of a selected polymer in a volatile organic solvent like methylene chloride. The mixture is then suspended in oil, such as silicon oil, by stirring, to form an emulsion. Within 24 hours, the solvent diffuses into the oil phase and the emulsion droplets harden into solid polymer microspheres. Unlike solvent evaporation, this method can be used to make microspheres from polymers with high melting points and a wide range of molecular weights. Microspheres having a diameter for example between one and 300 microns can be obtained with this procedure.
  • Targeting of Particles
  • Targeting molecules can be attached to the aerodynamically light particles via reactive functional groups on the particles. For example, targeting molecules can be attached to the amino acid groups of functionalized polyester graft copolymer particles, such as PLAL-Lys particles. Targeting molecules permit binding interaction of the particle with specific receptor sites, such as those within the lungs. The particles can be targeted by attachment of ligands which specifically or non-specifically bind to particular targets. Exemplary targeting molecules include antibodies and fragments thereof including the variable regions, lectins, and hormones or other organic molecules capable of specific binding for example to receptors on the surfaces of the target cells.
  • Therapeutic Agents
  • Any of a variety of therapeutic, prophylactic or diagnostic agents can be incorporated within the aerodynamically light particles. The aerodynamically light particles can be used to locally or systemically deliver a variety of therapeutic agents to an animal. Examples include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. The agents to be incorporated can have a variety of biological activities, such as vasoactive agents, neuroactive agents, hormones, anticoagulants, inimunomodulating agents, cytotoxic agents, prophylactic agents, antibiotics, antivirals, antisense, antigens, and antibodies. In some instances, the proteins may be antibodies or antigens which otherwise would have to be administered by injection to elicit an appropriate response. Compounds with a wide range of molecular weight can be encapsulated, for example, between 100 and 500,000 grams per mole.
  • Proteins are defined as consisting of 100 amino acid residues or more; peptides are less than 100 amino acid residues. Unless otherwise stated, the term protein refers to both proteins and peptides. Examples include insulin and other hormones. Polysaccharides, such as heparin, can also be administered.
  • The aerodynamically light polymeric aerosols are useful as carriers for a variety of inhalation therapies. They can be used to encapsulate small and large drugs, release encapsulated drugs over time periods ranging from hours to months, and withstand extreme conditions during aerosolization or following deposition in the lungs that might otherwise harm the encapsulated therapeutic.
  • The aerodynamically light particles may include a therapeutic agent for local delivery within the lung, such as agents for the treatment of asthma, emphysema, or cystic fibrosis, or for systemic treatment. For example, genes for the treatment of diseases such as cystic fibrosis can be administered, as can beta agonists for asthma. Other specific therapeutic agents include, but are not limited to, insulin, calcitonin, leuprolide (or LHRH), G-CSF, parathyroid hormone-related peptide, somatostatin, testosterone, progesterone, estradiol, nicotine, fentanyl, norethisterone, clonidine, scopolomine, salicylate, cromolyn sodium, salmeterol, formeterol, albuterol, and vallium.
  • Administration
  • The particles including a therapeutic agent may be administered alone or in any appropriate pharmaceutical carrier, such as a liquid, for example saline, or a powder, for administration to the respiratory system. They can be co-delivered with larger carrier particles, not including a therapeutic agent, the latter possessing mass mean diameters for example in the range 50 μm-100 μm.
  • Aerosol dosage, formulations and delivery systems may be selected for a particular therapeutic application, as described, for example, in Gonda, I. “Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract,” in Critical Reviews in Therapeutic Drug Carrier Systems, 6:273-313, 1990; and in Moren, “Aerosol dosage, forms and formulations,” in: Aerosols in Medicine. Principles, Diagnosis and Therapy, Moren, et al., Eds, Esevier, Amsterdam, 1985, the disclosures of which are incorporated herein by reference.
  • The greater efficiency of aerosolization by aerodynamically light particles of relatively large size permits more drug to be delivered than is possible with the same mass of non-light aerosols. The relatively large size of aerodynamically light aerosols depositing in the deep lungs also minimizes potential drug losses caused by particle phagocytosis. The use of aerodynamically light polymeric aerosols as therapeutic carriers provides the benefits of biodegradable polymers for controlled release in the lungs and long-time local action or systemic bioavailability. Denaturation of macromolecular drugs can be minimized during aerosolization since macromolecules are contained and protected within a polymeric shell. Coencapsulation of peptides with peptidase-inhibitors can minimize peptide enzymatic degradation.
  • The present invention will be further understood by reference to the following non-limiting examples.
  • EXAMPLE 1 Synthesis of Aerodynamically Light Poly[(p-carboxyphenoxy)-hexane anhydride] (“PCPH”) Particles
  • Aerodynamically light poly[(p-carboxyphenoxy)-hexane anhydride] (“PCPH”) particles were synthesized as follows. 100 mg PCPH (MW˜25,000) was dissolved in 3.0 mL methylene chloride. To this clear solution was added 5.0 mL, 1% w/v aqueous polyvinyl alcohol (PVA, MW˜25,000, 88 mole % hydrolyzed) saturated with methylene chloride, and the mixture was vortexed (Vortex Genie 2, Fisher Scientific) at maximum speed for one minute. The resulting milky-white emulsion was poured into a beaker containing 95 mL 1% PVA and homogenized (Silverson Homogenizers) at 6000 RPM for one minute using a 0.75 inch tip. After homogenization, the mixture was stirred with a magnetic stirring bar and the methylene chloride quickly extracted from the polymer particles by adding 2 mL isopropyl alcohol. The mixture was continued to stir for 35 minutes to allow complete hardening of the microparticles. The hardened particles were collected by centrifugation and washed several times with double distilled water. The particles were freeze dried to obtain a free-flowing powder void of clumps. Yield, 85-90%.
  • The mean diameter of this batch was 6.0 μm, however, particles with mean diameters ranging from a few hundred nanometers to several millimeters may be made with only slight modifications. Scanning electron micrograph photos of a typical batch of PCPH particles showed the particles to be highly porous with irregular surface shape. The particles have a tap density less than 0.4 g/cm3.
  • EXAMPLE 2 Synthesis of PLAL-Lys and PLAL-Lys-Ala Polymeric and Copolymeric Particles
  • Aerodynamically Light PLAL-Lys Particles
  • PLAL-Lys particles were prepared by dissolving 50 mg of the graft copolymer in 0.5 ml dimethylsulfoxide, then adding 1.5 ml dichloromethane dropwise. The polymer solution is emulsified in 100 ml of 5% w/v polyvinyl alcohol solution (average molecular weight 25 KDa, 88% hydrolyzed) using a homogenizer (Silverson) at a speed of approximately 7500 rpm. The resulting dispersion is stirred using a magnetic stirrer for 1 hour. Following this period, the pH is brought to 7.0-7.2 by addition of 0.1 N NaOH solution. Stirring is continued for an additional 2 hours until the methylene chloride is completely evaporated and the particles hardened. The particles are then isolated by centrifugation at 4000 rpm (1600 g) for 10 minutes (Sorvall RC-5B). The supernatant is discarded and the precipitate washed three times with distilled water followed by centrifugation for 10 minutes at 4000 rpm each time. Finally, the particles are resuspended in 5 ml of distilled water, the dispersion frozen in liquid nitrogen, and lyophilized (Labconco freeze dryer 8) for at least 48 hours. Particle sizing is performed using a Coulter counter. Average particle mean diameters ranged from 100 nm to 14 μm, depending upon processing parameters such as homogenization speed and time. All particles exhibited tap densities less than 0.4 g/cm3. Scanning electron micrograph photos of the particles showed them to be highly porous with irregular surfaces.
  • Aerodynamically Light PLAL-Ala-Lys Particles
  • 100 mg of PLAL-Ala-Lys is completely dissolved in 0.4 ml trifluoroethanol, then 1.0 ml methylene chloride is added dropwise. The polymer solution is emulsified in 100 ml of 1% w/v polyvinyl alcohol solution (average molecular weight 25 KDa, 80% hydrolyzed) using a sonicator (Sonic&Materal VC-250) for 15 seconds at an output of 40 W. 2 ml of 1% PVA solution is added to the mixture and it is vortexed at the highest speed for 30 seconds. The mixture is quickly poured into a beaker containing 100 ml 0.3% PVA solution, and stirred for three hours allowing evaporation of the methylene chloride. Scanning electron micrograph photos of the particles showed them to possess highly irregular surfaces.
  • Aerodynamically Light Copolymer Particles
  • Polymeric aerodynamically light particles consisting of a blend of PLAL-Lys and PLGA-PEG were made. 50 mg of the PLGA-PEG polymer (molecular weight of PEG: 20 KDa, 1:2 weight ratio of PEG:PLGA, 75:25 lactide:glycolide) was completely dissolved in 1 ml dichloromethane. 3 mg of poly(lactide-co-lysine)-polylysine graft copolymer is dissolved in 0.1 ml dimethylsulfoxide and mixed with the first polymer solution. 0.2 ml of TE buffer, pH 7.6, is emulsified in the polymer solution by probe sonication (Sonic&Materal VC-250) for 10 seconds at an output of 40 W. To this first emulsion, 2 ml of distilled water is added and mixed using a vortex mixer at 4000 rpm for 60 seconds. The resulting dispersion is agitated by using a magnetic stirrer for 3 hours until methylene chloride is completely evaporated and microspheres formed. The spheres are then isolated by centrifugation at 5000 rpm for 30 min. The supernatant is discarded, the precipitate washed three times with distilled water and resuspended in 5 ml of water. The dispersion is frozen in liquid nitrogen and lyophilized for 48 hours.
  • Variables which may be manipulated to alter the size distribution of the particles include: polymer concentration, polymer molecular weight, surfactant type (e.g., PVA, PEG, etc.), surfactant concentration, and mixing intensity. Variables which may be manipulated to alter the surface shape and porosity of the particles include: polymer concentration, polymer molecular weight, rate of methylene chloride extraction by isopropyl alcohol (or another miscible solvent), volume of isopropyl alcohol added, inclusion of an inner water phase, volume of inner water phase, inclusion of salts or other highly water-soluble molecules in the inner water phase which leak out of the hardening sphere by osmotic pressure, causing the formation of channels, or pores, in proportion to their concentration, and surfactant type and concentration.
  • By scanning electron microscopy (SEM), the PLAL-Lys-PLGA-PEG particles were highly surface rough and porous. The partictes had a mean particle diameter of 7 μm. The blend of PLAL-Lys with poly(lactic acid) (PLA) and/or PLGA-PEG copolymers can be adjusted to adjust particle porosity and size. Additionally, processing parameters such as homogeruization speed and time can be adjusted. Neither PLAL, PLA nor PLGA-PEG alone yields an aerodynamically light structure when prepared by these techniques.
  • EXAMPLE 3 Synthesis of Spray-Dried Particles
  • Aerodynamically Light Particles Containing Polymer and Drug Soluble in Common Solvent
  • Aerodynamically light 50:50 PLGA particles were prepared by spray drying with testosterone encapsulated within the particles according to the following procedures. 2.0 g poly (D,L-lactic-co-glycolic acid) with a molar ratio of 50:50 (PLGA 50:50, Resomer RG503, B.I. Chemicals, Montvale, N.J.) and 0.50 g testosterone (Sigma Chemical Co., St. Louis, Mo.) are completely dissolved in 100 mL dichloromethane at room temperature. The mixture is subsequently spray-dried through a 0.5 mm nozzle at a flow rate of 5 mL/min using a Buchi laboratory spray-drier (model 190, Buchi, Germany). The flow rate of compressed air is 700 nl/h. The inlet temperature is set to 30° C. and the outlet temperature to 25° C. The aspirator is set to achieve a vacuum of −20 to −25 bar. The yield is 51% and the mean particle size is approximately 5 μm. Larger particle size can be achieved by lowering the inlet compressed air flow rate, as well as by changing other variables. The particles are aerodynamically light, as determined by a tap density less than or equal to 0.4 g/cm3. Porosity and surface roughness can be increased by varying the inlet and outlet temperatures, among other factors.
  • Aerodynamically Light Particles Containing Polymer and Drug in Different Solvents
  • Aerodynamically light PLA particles with a model hydrophilic drug (dextran) were prepared by spray drying using the following procedure. 2.0 mL of an aqueous 10% w/v FITC-dextran (MW 70,000, Sigma Chemical Co.) solution was emulsified into 100 mL of a 2% w/v solution of poly (D,L-lactic acid) (PLA, Resomer R206, B.I. Chemicals) in dichloromethane by probe sonication (Vibracell Sonicator, Branson). The emulsion is subsequently spray-dried at a flow rate of 5 mL/min with an air flow rate of 700 nl/h (inlet temperature=30° C., outlet temperature=21° C., −20 mbar vacuum). The yield is 56%. The particles are aerodynamically light, as determined by a tap density of less than 0.4 g/cm3.
  • Aerodynamically Light Protein Particles
  • Aerodynamically light lysozyme particles were prepared by spray drying using the following procedure. 4.75 g lysozyme (Sigma) was dissolved in 95 mL double distilled water (5% w/v solution) and spray-dried using a 0.5 mm nozzle and a Buchi laboratory spray-drier. The flow rate of compressed air was 725 nl/h. The flow rate of the lysozyme solution was set such that, at a set inlet temperature of 97-100° C., the outlet temperature is 55-57° C. The aspirator was set to achieve a vacuum of −30 mbar. The enzymatic activity of lysozyme was found to be unaffected by this process and the yield of the aerodynamically light particles (tap density less than 0.4 g/cm3) was 66%.
  • Aerodynamically Light High-Molecular Weight Water Soluble Particles
  • Aerodynamically light dextran particles were prepared by spray drying using the following procedure. 6.04 g DEAE dextran (Sigma) was dissolved in 242 mL double distilled water (2.5% w/v solution) and spray-dried using a 0.5 mm nozzle and a Buchi laboratory spray-drier. The flow rate of compressed air was 750 nl/h. The flow rate of the DEAE-dextran solution was set such that, at a set inlet temperature of 155° C., the outlet temperature was 80° C. The aspirator was set to achieve a vacuum of −20 mbar. The yield of the aerodynamically light particles (tap density less than 0.4 g/cm3) was 66% and the size range ranged between 1-15 μm.
  • Aerodynamically Light Low-Molecular Weight Water-Soluble Particles
  • Aerodynamically light trehalose particles were prepared by spray drying using the following procedure. 4.9 g trehalose (Sigma) was dissolved in 192 mL double distilled water (2.5% w/v solution) and spray-dried using a 0.5 mm nozzle and a Buchi laboratory spray-drier. The flow rate of compressed air was 650 nl/h. The flow rate of the trehalose solution was set such that, at a set inlet temperature of 100° C., the outlet temperature was 60° C. The aspirator was set to achieve a vacuum of −30 mbar. The yield of the aerodynamically light particles (tap density less than 0.4 g/cm3) was 36% and the size range ranged between 1-15 μm.
  • Aerodynamically Light Low-Molecular Weight Water-Soluble Particles
  • Polyethylene glycol (PEG) is a water-soluble macromolecule, however, it cannot be spray dried from an aqueous solution since it melts at room temperatures below that needed to evaporate water. As a result, we have spray-dried PEG at low temperatures from a solution in dichloromethane, a low boiling organic solvent. Aerodynamically light PEG particles were prepared by spray drying using the following procedure. 5.0 g PEG (MW 15,000-20,000, Sigma) was dissolved in 100 mL double distilled water (5.0% w/v solution) and spray-dried using a 0.5 mm nozzle and a Buchi laboratory spray-drier. The flow rate of compressed air 750 nl/h. The flow rate of the PEG solution was set such that, at a set inlet temperature of 45° C., the outlet temperature was 34-35° C. The aspirator was set to achieve a vacuum of −22 mbar. The yield of the aerodynamically light particles (tap density less than 0.4 g/cm3) was 67% and the size range ranged between 1-15 μm.
  • EXAMPLE 4 Rhodarnine Isothiocyanate Labeling of PLAL and PLAL-Lys Particles
  • Aerodynamically light particles were compared with control particles, referred to herein as “non-light” particles. Lysine amine groups on the surface of aerodynamically light (PLAL-Lys) and control, non-light (PLAL) particles, with similar mean diameters (6-7 μm) and size distributions (standard deviations 3-4 μm) were labeled with Rhodamine isothiocyanate. The tap density of the porous PLAL-Lys particles was 0.1 g/cm3 and that of the non-light PLAL particles was 0.8 g/cm3.
  • The rhodamine-labeled particles were characterized by confocal microscopy. A limited number of lysine functionalities on the surface of the solid particle were able to react with rhodamine isothiocyanate, as evidenced by the fluorescent image. In the aerodynamically light particle, the higher lysine content in the graft copolymer and the porous particle structure result in a higher level of rhodamine attachment, with rhodamine attachment dispersed throughout the intersticies of the porous structure. This also demonstrates that targeting molecules can be attached to the aerodynamically light particles for interaction with specific receptor sites within the lungs via chemical attachment of appropriate targeting agents to the particle surface.
  • EXAMPLE 5 Aerosolization of PLAL and PLAL-Lys Particles
  • To determine whether large aerodynamically light particles can escape (mouth, throat and inhaler) deposition and more efficiently enter the airways and acini than nonporous particles of similar size (referred to herein as nonlight or control particles), aerosolization and deposition of aerodynamically light PLAL-Lys (mean diameter 6.3 μm) or control, non-light PLAL (mean diameter 6.9 μm) particles were examined in vitro using a cascade impactor system.
  • 20 mg of the aerodynamically light or non-light microparticles were placed in gelatine capsules (Eli Lilly), the capsules loaded into a Spinhaler dry powder inhaler (DPI) (Fisons), and the DPI activated. Particles were acrosolized into a Mark I Andersen Impactor (Andersen Samplers, GA) from the DPI for 30 seconds at 28.3 l/min flow rate. Each plate of the Andersen Impactor was previously coated with Tween 80 by immersing the plates in an acetone solution (5% w/vol) and subsequently evaporating the acetone in a oven at 60° C. for 5 min. After aerosolization and deposition, particles were collected from each stage of the impactor system in separate volumetric flasks by rinsing each stage with a NaOH solution (0.2 N) in order to completely degrade the polymers. After incubation at 37° C. for 12 h, the fluorescence of each solution was measured (wavelengths of 554 nm excitation, 574 nm emission).
  • Particles were determined as nonrespirable (mean aerodynamic diameter exceeding 4.7 μm: impactor estimate) if they deposited on the first three stages of the impactor, and respirable (mean aerodynamic diameter 4.7 μm or less) if they deposited on subsequent stages. FIG. 1 shows that less than 10% of the non-light (PLAL) particles that exit the DPI are respirable. This is consistent with the large size of the microparticles and their standard mass density. On the other hand, greater than 55% of the aerodynamically light (PLAL-Lys) particles are respirable, even though the geometrical dimensions of the two particle types are almost identical. The lower tap density of the aerodynamically light (PLAL-Lys) microparticles is responsible for this improvement in particle penetration, as discussed further below.
  • The non-light (PLAL) particles also inefficiently aerosolize from the DPI; typically, less than 40% of the non-light particles exited the Spinhaler DPI for the protocol used. The aerodynamically light (PLAL-Lys) particles exhibited much more efficient aerosolization (approximately 80% of the aerodynamically light microparticles typically exited the DPI during aerosolization).
  • The combined effects of efficient aerosolization and high respirable fraction of aerosolized particle mass means that a far greater fraction of an aerodynamically light particle powder is likely to deposit in the lungs than of a non-light particle powder.
  • EXAMPLE 6 In Vivo Aerosolization of PLAL and PLAL-lys Particles
  • The penetration of aerodynamically light and non-light polymeric PLAL-Lys and PLAL microparticles into the lungs was evaluated in an in vivo experiment involving the aerosolization of the microparticles into the airways of live rats.
  • Male Spraque Dawley rats (150-200 g) were anesthetized using ketamine (90 mg/kg)/xylazine (10 mg/kg). The anesthetized rat was placed ventral side up on a surgical table provided with a temperature controlled pad to maintain physiological temperature. The animal was cannulated above the carina with an endotracheal tube connected to a Harvard ventilator. The animal was force ventilated for 20 minutes at 300 ml/min. 50 mg of aerodynamically light (PLAL-Lys) or non-light (PLA) microparticles were introduced into the endotracheal tube.
  • Following the period of forced ventilation, the animal was euthanized and the lungs and trachea were separately washed using bronchoalveolar lavage. A tracheal cannula was inserted, tied into place, and the air-ways were washed with 10 ml aliquots of HBSS. The lavage procedure was repeated until a total volume of 30 ml was collected. The lavage fluid was centrifuged (400 g) and the pellets collected and resuspended in 2 ml of phenol red-free Hanks balanced salt solution (Gibco, Grand Island, N.Y.) without Ca2+ and Mg2+ (HBSS). 100 ml were removed for particle counting using a hemacytometer. The remaining solution was mixed with 10 ml of 0.4 N NaOH. After incubation at 37° C. for 12 h, the fluorescence of each solution was measured (wavelengths of 554 nm excitation, 574 nm emission).
  • FIG. 2 is a bar graph showing total particle mass deposited in the trachea and after the carina (lungs) in rat lungs and upper airways following intratracheal aerosolization during forced ventilation. The PLAL-Lys aerodynamically light particles had a mean diameter 6.9 μm. The non-light PLAL particles had a mean diameter of 6.7 μm. Percent tracheal aerodynamically light particle deposition was 54.5, and non-light deposition was 77.0. Percent aerodynamically light particle deposition in the lungs was 46.8 and non-light deposition was 23.0.
  • The non-light (PLAL) particles deposited primarily in the trachea (approximately 79% of all particle mass that entered the trachea). This result is similar to the in vitro performance of the non-light microparticles and is consistent with the relatively large size of the nonlight particles. Approximately 54% of the aerodynamically light (PLAL-Lys) particle mass deposited in the trachea. Therefore, about half of the aerodynamically light particle mass that enters the trachea traverses through the trachea and into the airways and acirii of the rat lungs, demonstrating the effective penetration of the aerodynamically light particles into the lungs.
  • Following bronchoalveolar lavage, particles remaining in the rat lungs were obtained by careful dissection of the individual lobes of the lungs. The lobes were placed in separate petri dishes containing 5 ml of HBSS. Each lobe was teased through 60 mesh screen to dissociate the tissue and was then filtered through cotton gauze to remove tissue debris and connective tissue. The petri dish and gauze were washed with an additional 15 ml of HBSS to maximize microparticle collection. Each tissue preparation was centrifuged and resuspended in 2 ml of HBSS and the number of particles counted in a hemacytometer. The particle numbers remaining in the lungs following the bronchoalveolar lavage are shown in FIG. 3. Lobe numbers correspond to: 1) left lung, 2) anterior, 3) median, 4) posterior, 5) postcaval. A considerably greater number of aerodynamically light PLAL-Lys particles enters every lobe of the lungs than the nonlight PLAL particles, even though the geometrical dimensions of the two types of particles are essentially the same. These results reflect both the efficiency of aerodynamically light particle aerosolization and the propensity of the aerodynamically light particles to escape deposition prior to the carina or first bifurcation.
  • Modifications and variations of the present invention will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the following claims.

Claims (23)

1. A mass of biocompatible particles, suitable for pulmonary delivery, comprising particles having therapeutic, prophylactic or diagnostic agent, and having a mass mean diameter of at least 6.5 μm and an aerodynamic diameter of less than 4 μm, wherein at least 46% of the mass of particles are deposited after the first bifurcation of the lungs.
2. The particles of claim 1 wherein the particles have a mass mean diameter between 6.5 μm and 30 μm.
3. The particles of claim 1 wherein the particles have an aerodynamic diameter of less than 3 μm.
4. The particles of claim 1 wherein the agent is selected from the group consisting of proteins, polysaccharides, lipids, nucleic acids, beta agonists and combinations thereof.
5. The particles of claim 1 wherein the agent is selected from the group consisting of insulin, calcitonin, leuprolide, LHRH, granulocyte colony stimulating factor, parathyroid hormone-related peptide, somatostatin, testosterone, progesterone, estradiol, nicotine, fentanyl, norethisterone, clonidine, scopolomine, salicylate, cromolyn sodium, salmeterol, formeterol, albuterol, and vallium.
6. The particles of claim 1 wherein the particles further comprise a biodegradable material.
7. The particles of claim 6 wherein the biodegradable material is a polymeric material.
8. The particles of claim 6 wherein the biodegradable material is a non-polymeric material.
9. The particles of claim 1 wherein the particles have a tap density of less than about 0.4 g/cm3.
10. The particles of claim 9 wherein the particles have a tap density of less than about 0.1 g/cm3.
11. A method for delivery of a therapeutic, prophylactic or diagnostic agent to the pulmonary system comprising:
administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of biocompatible particles, wherein the particles comprising a therapeutic, prophylactic or diagnostic agent, and have a mass mean diameter of at least 6.5 μm and an aerodynamic diameter of less than 4 μm, wherein 46% of the mass of said particles delivered are deposited after the first bifurcation of the lungs.
12. The method of claim 11 wherein the particles have a mass mean diameter between 6.5 μm and 30 μm.
13. The method of claim 11 wherein the particles have an aerodynamic diameter of less than 3 μm.
14. The method of claim 11 wherein the agent is selected from the group consisting of proteins, polysaccharides, lipids, nucleic acids, beta agonists and combinations thereof.
15. The method of claim 11 wherein the agent is selected from the group consisting of insulin, calcitonin, leuprolide, LHRH, granulocyte colony stimulating factor, parathyroid hormone-related peptide, somatostatin, testosterone, progesterone, estradiol, nicotine, fentanyl, norethisterone, clonidine, scopolomine, salicylate, cromolyn sodium, salmeterol, formeterol, albuterol, and vallium.
16. The method of claim 11 wherein the particles further comprise a biodegradable material.
17. The method of claim 16 wherein the biodegradable material is a polymeric material.
18. The method of claim 16 wherein the biodegradable material is a non-polymeric material.
19. The method of claim 11 wherein the particles have a tap density of less than about 0.4 g/cm3.
20. The method of claim 19 wherein the particles have a tap density of less than about 0.1 g/cm3.
21. The method of claim 11 wherein the agent is delivered to the deep lung.
22. The method of claim 11 wherein the agent is delivered to the central airways.
23. A particulate composition suitable for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent, comprising particles having a tap density less than 0.4 g/cm3, wherein more than 50% of the particles are respirable.
US11/064,065 1996-05-24 2005-02-23 Aerodynamically light particles for pulmonary drug delivery Abandoned US20050158249A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US65557096A true 1996-05-24 1996-05-24
US08/739,308 US5874064A (en) 1996-05-24 1996-10-29 Aerodynamically light particles for pulmonary drug delivery
US09/211,940 US6136295A (en) 1996-05-24 1998-12-15 Aerodynamically light particles for pulmonary drug delivery
US09/562,988 US6399102B1 (en) 1996-05-24 2000-05-01 Aerodynamically light particles for pulmonary drug delivery
US10/027,212 US6635283B2 (en) 1996-05-24 2001-12-20 Aerodynamically light particles for pulmonary drug delivery
US10/441,948 US6942868B2 (en) 1996-05-24 2003-05-20 Aerodynamically light particles for pulmonary drug delivery
US11/064,065 US20050158249A1 (en) 1996-05-24 2005-02-23 Aerodynamically light particles for pulmonary drug delivery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/064,065 US20050158249A1 (en) 1996-05-24 2005-02-23 Aerodynamically light particles for pulmonary drug delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/441,948 Continuation US6942868B2 (en) 1996-05-24 2003-05-20 Aerodynamically light particles for pulmonary drug delivery

Publications (1)

Publication Number Publication Date
US20050158249A1 true US20050158249A1 (en) 2005-07-21

Family

ID=27096992

Family Applications (6)

Application Number Title Priority Date Filing Date
US08/739,308 Expired - Lifetime US5874064A (en) 1996-05-24 1996-10-29 Aerodynamically light particles for pulmonary drug delivery
US09/211,940 Expired - Lifetime US6136295A (en) 1996-05-24 1998-12-15 Aerodynamically light particles for pulmonary drug delivery
US09/562,988 Expired - Lifetime US6399102B1 (en) 1996-05-24 2000-05-01 Aerodynamically light particles for pulmonary drug delivery
US10/027,212 Expired - Lifetime US6635283B2 (en) 1996-05-24 2001-12-20 Aerodynamically light particles for pulmonary drug delivery
US10/441,948 Expired - Fee Related US6942868B2 (en) 1996-05-24 2003-05-20 Aerodynamically light particles for pulmonary drug delivery
US11/064,065 Abandoned US20050158249A1 (en) 1996-05-24 2005-02-23 Aerodynamically light particles for pulmonary drug delivery

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US08/739,308 Expired - Lifetime US5874064A (en) 1996-05-24 1996-10-29 Aerodynamically light particles for pulmonary drug delivery
US09/211,940 Expired - Lifetime US6136295A (en) 1996-05-24 1998-12-15 Aerodynamically light particles for pulmonary drug delivery
US09/562,988 Expired - Lifetime US6399102B1 (en) 1996-05-24 2000-05-01 Aerodynamically light particles for pulmonary drug delivery
US10/027,212 Expired - Lifetime US6635283B2 (en) 1996-05-24 2001-12-20 Aerodynamically light particles for pulmonary drug delivery
US10/441,948 Expired - Fee Related US6942868B2 (en) 1996-05-24 2003-05-20 Aerodynamically light particles for pulmonary drug delivery

Country Status (10)

Country Link
US (6) US5874064A (en)
EP (1) EP0907356B1 (en)
JP (2) JP4315468B2 (en)
AT (1) AT215357T (en)
CA (1) CA2255564C (en)
DE (2) DE69711626D1 (en)
DK (1) DK0907356T3 (en)
ES (1) ES2175420T3 (en)
PT (1) PT907356E (en)
WO (1) WO1997044013A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244341A1 (en) * 1997-05-23 2005-11-03 Edwards David A Aerodynamically light particles for pulmonary drug delivery
US7928089B2 (en) 2003-09-15 2011-04-19 Vectura Limited Mucoactive agents for treating a pulmonary disease
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
US9724664B2 (en) 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process

Families Citing this family (457)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
KR100252447B1 (en) 1995-06-02 2000-04-15 아르므 엠. 무센 Raised tungsten plug antifuse and fabrication process
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
ZA9711385B (en) * 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6001336A (en) 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6153211A (en) 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
AR014940A1 (en) * 1997-12-12 2001-04-11 Expression Genetics Inc A carrier for the release of a bioactive agent, a biodegradable polyester polymer, copolymers and pharmaceutical compositions loscontienen.
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2336139C (en) * 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
MA25590A1 (en) 1998-09-14 2002-12-31 Inhale Therapeutic Syst active agent dry powder Shipping Policy
US8933032B2 (en) 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
AT363892T (en) * 1999-03-05 2007-06-15 Chiesi Farma Spa Improved powder formulations for inhalation
US20050214227A1 (en) * 1999-03-08 2005-09-29 Powderject Research Limited Microparticle formulations for sustained-release of bioactive compounds
WO2000065521A2 (en) 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
JP2003501404A (en) * 1999-06-04 2003-01-14 ウィリアムズ,ロバート,オー.,スリー Formulations and this method of preparation consists of dehydrated particles of the drug
DK1808438T3 (en) * 1999-06-29 2014-10-27 Mannkind Corp Purification and stabilization of peptide and protein drugs in
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6749835B1 (en) * 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6676930B2 (en) 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
WO2001045731A1 (en) * 1999-12-21 2001-06-28 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
CZ20022265A3 (en) * 1999-12-30 2004-01-14 Chiron Corporation Medicament for administering interleukin-2 and a stabilized lyophilized or spray dried pharmaceutical preparation containing interleukin-2
WO2001051030A1 (en) * 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
AU3100001A (en) 2000-01-19 2001-07-31 Pharmaceutical Discovery Corp Dry powder formulations of antihistamine for nasal administration
AT474854T (en) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralizing antibody with very high affinity
CA2400172C (en) 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
ES2527853T3 (en) * 2000-03-08 2015-01-30 Massachusetts Institute Of Technology Heparinase III and their uses
EP1265626B1 (en) * 2000-03-14 2014-09-10 National Jewish Health Method for reducing allergen-induced airway hyperresponsiveness
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
ES2525087T5 (en) * 2000-05-10 2018-06-28 Novartis Ag phospholipid based powders drug delivery
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
AU8093401A (en) * 2000-07-28 2002-02-13 Alliance Pharma Novel methods and compositions to upregulate, redirect or limit immune responsesto peptides, proteins and other bioactive compounds and vectors expressing the same
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
PT1319183E (en) 2000-09-12 2009-06-29 Massachusetts Inst Technology Methods and products related to low molecular weight heparin
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
GB0028268D0 (en) * 2000-11-20 2001-01-03 Norske Stats Oljeselskap Well treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
TWI327600B (en) 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AT446085T (en) * 2000-11-30 2009-11-15 Vectura Ltd Particles for use in a pharmaceutical composition
WO2002043705A2 (en) * 2000-12-01 2002-06-06 University Of Florida Aerodynamically light vaccine for active pulmonary immunization
US20020128179A1 (en) * 2000-12-01 2002-09-12 Tacon William C. Shaped microparticles for pulmonary drug delivery
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
JP4986370B2 (en) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオMax−Planck−Gesellschaft zur Foerderung der Wissenschaften e.V. Use of Rgm and the modulator
JP4731793B2 (en) * 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド Crystals whole antibodies or fragments thereof, and methods for making and using this crystal
WO2002053190A2 (en) * 2000-12-29 2002-07-11 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
AU2002303869B2 (en) * 2001-05-21 2007-08-16 Novartis Ag Pulmonary administration of chemically modified insulin
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
CA2447519C (en) 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20040146540A1 (en) * 2001-06-12 2004-07-29 Kazue Ueda Cosmetic
JP2005500304A (en) * 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド Globular protein particles and and using manufacturing thereof
US6730772B2 (en) * 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
US6921390B2 (en) * 2001-07-23 2005-07-26 Boston Scientific Scimed, Inc. Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface
DE10137102A1 (en) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalent vaccine against diseases caused by papilloma viruses, processes for their preparation and their use
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
JP2005507881A (en) 2001-09-17 2005-03-24 グラクソ グループ リミテッドGlaxo Group Limited Dry powder pharmaceutical formulations
EP1446104B2 (en) 2001-11-01 2011-08-03 Novartis AG Spray drying methods
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US7182961B2 (en) * 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
AU2002346472A1 (en) * 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
AU2002364701B8 (en) * 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
US20030168057A1 (en) * 2001-12-14 2003-09-11 Inhale Therapeutic Systems, Inc. Electronically controllable aerosol delivery
MXPA04005865A (en) 2001-12-19 2004-09-13 Nektar Therapeutics Pulmonary delivery of aminoglycosides.
EP1480691A4 (en) * 2002-03-05 2007-11-28 Univ State Cleveland Agglomerated particles for aerosol drug delivery
JP2005526769A (en) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Central airways administration for systemic transport the therapeutic agent
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
PT2494962E (en) * 2002-03-20 2014-08-27 Civitas Therapeutics Inc Pulmonary delivery for levodopa
WO2003079993A2 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
WO2003087189A1 (en) * 2002-04-05 2003-10-23 Valorisation - Recherche, Societe En Commandite Functionalized polymers and their biomedical and pharmaceutical uses
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College Formulations limiting spread of pulmonary infections
CA2483687A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
DE10234165B4 (en) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale A method of filling a trench formed in a substrate, with an insulating material
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc Fcgammariib-specific antibodies, and methods of use thereof
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
EP3301114A1 (en) 2002-10-16 2018-04-04 Purdue Pharma LP Fusion polypeptides of antibodies that bind cell-associated ca 125/o722p
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
DK1567164T3 (en) 2002-11-26 2009-05-18 Alexza Pharmaceuticals Inc Use of Loxapine for the manufacture of a medicament for the treatment of pain
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040206350A1 (en) * 2002-12-19 2004-10-21 Nektar Therapeutics Aerosolization apparatus with non-circular aerosolization chamber
EP1578536B1 (en) 2002-12-30 2017-02-08 Novartis AG Prefilming atomizer
EP1581182A2 (en) * 2002-12-31 2005-10-05 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
US20040156792A1 (en) * 2002-12-31 2004-08-12 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
BRPI0406724A (en) 2003-01-13 2005-12-20 Macrogenics Inc Dimeric fusion protein, methods for treating, preventing or ameliorating one or more symptoms of an autoimmune disorder and one or more symptoms of idiopathic thrombocytopenic purpura, pharmaceutical composition, nucleic acid, vector, host cell, method of producing the polypeptide recombinantly, isolated polypeptide fragment of any of the polypeptides, and isolated nucleic acid molecule
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β (1-42) oligomers, processes for their preparation and their use
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
US7559325B2 (en) * 2003-04-09 2009-07-14 Novartis Pharma Ag Aerosolization apparatus with air inlet shield
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
EP1625333A1 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
GB0313604D0 (en) * 2003-06-12 2003-07-16 Britannia Pharmaceuticals Ltd Delivery device for powdered medicament
WO2004112799A1 (en) * 2003-06-13 2004-12-29 Chrysalis Technologies Incorporated Methods and apparatus for producing nanoscale particles
WO2004112702A2 (en) * 2003-06-13 2004-12-29 Advanced Inhalation Research, Inc. Low dose pharmaceutical powders for inhalation
US20050032173A1 (en) * 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
WO2005025506A2 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
BRPI0414907A (en) * 2003-09-30 2006-11-07 Acusphere Inc Pharmaceutical formulations with sustained intravenous, oral or topical release
JP2007507527A (en) * 2003-09-30 2007-03-29 スフェリックス, インコーポレイテッド Therapeutic agents biologically active nanoparticles
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
KR100985126B1 (en) * 2004-01-12 2010-10-05 맨카인드 코포레이션 A method of reducing serum proinsulin levels in type 2 diabetics
US20060019914A1 (en) * 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
ES2398838T3 (en) * 2004-03-12 2013-03-22 Biodel, Inc. Delivery compositions rapid acting drug
BRPI0510735A (en) * 2004-05-07 2007-11-20 Harvard College formulation of particulate vaccine method for making a formulation of particulate vaccine and vaccination method
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
JP2007537833A (en) * 2004-05-20 2007-12-27 ディスカバリー ラボラトリーズ,インコーポレイテッド The method for noninvasive pulmonary inhalation, systems, and devices
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
WO2006002140A2 (en) * 2004-06-21 2006-01-05 Nektar Therapeutics Compositions comprising amphotericin b
KR20070054644A (en) * 2004-07-26 2007-05-29 액테리온 파마슈티칼 리미티드 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
EP1785145A4 (en) * 2004-08-10 2008-08-13 Translational Res Ltd Transnasal composition having immediate action and high absorbability
US20100006092A1 (en) * 2004-08-12 2010-01-14 Alexza Pharmaceuticals, Inc. Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
CA2576961A1 (en) * 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP2008518936A (en) * 2004-10-29 2008-06-05 メディミューン,インコーポレーテッド How to prevent and treat Rsv infections and related conditions
DE102004053373A1 (en) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Invention relating anisometric particles in the form of nano / meso fibers Tubes, cables may tapes and their curved or branched modifications
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
EP1848410A4 (en) * 2005-02-17 2011-11-09 Medivas Llc Polymer particle delivery compositions and methods of use
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
JP5838021B2 (en) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド Covalent diabody and its use
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
AU2006247077A1 (en) * 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US20110177996A1 (en) * 2005-05-23 2011-07-21 Children's Hospital Medical Center Regulatory proteins in lung repair and treatment of lung disease
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
JP2008546805A (en) 2005-06-23 2008-12-25 メディミューン,エルエルシー Antibody preparation with optimal aggregation and fragmentation profile
CN103145839A (en) * 2005-06-30 2013-06-12 Abbvie 公司 IL-12/P40 binding proteins
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
PT1919503E (en) 2005-08-10 2015-01-05 Macrogenics Inc Identification and engineering of antibodies with variant fc regions and methods of using same
JP2009508472A (en) * 2005-08-11 2009-03-05 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Methods and compositions for dry cell morphology
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20120060245A (en) 2005-09-14 2012-06-11 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
JP5192384B2 (en) 2005-09-22 2013-05-08 メディバス エルエルシー Bis - (alpha-amino) - diol - diester containing poly (ester amides) and poly (ester urethane) compositions and method of use
US20070292476A1 (en) * 2006-05-02 2007-12-20 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
EP1933881B1 (en) * 2005-09-22 2019-03-13 Medivas, LLC Solid polymer delivery compositions and methods for use thereof
WO2007036501A2 (en) * 2005-09-26 2007-04-05 Basf Aktiengesellschaft Graft copolymer and use of the same
AU2006297394B9 (en) * 2005-09-29 2013-09-19 Novartis Ag Receptacles and kits, such as for dry powder packaging
AU2007238114B2 (en) * 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1928905B1 (en) * 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
WO2007053923A2 (en) * 2005-11-11 2007-05-18 Biolab Sanus Farmacêutica Ltda. Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same
WO2008048298A2 (en) * 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
AU2006320392B2 (en) 2005-11-30 2013-01-17 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
PT1954718E (en) * 2005-11-30 2014-12-16 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007067744A2 (en) * 2005-12-07 2007-06-14 Medivas, Llc Method for assembling a polymer-biologic delivery composition
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
JP5599975B2 (en) * 2006-02-22 2014-10-01 マンカインド コーポレイション Method for improving the formulation properties of the fine particles containing diketopiperazine and an active agent
US8968702B2 (en) * 2006-03-30 2015-03-03 Duke University Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
EP2007358A4 (en) * 2006-04-04 2012-01-25 Stc Unm Swellable particles for drug delivery
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20090317335A1 (en) * 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
WO2007133616A2 (en) * 2006-05-09 2007-11-22 Medivas, Llc Biodegradable water soluble polymers
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB-specific antibodies and methods of use thereof
TW201343676A (en) 2006-08-28 2013-11-01 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
KR101544108B1 (en) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 Binding protein interleukin -13
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
EP2425819A1 (en) * 2007-02-11 2012-03-07 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US10280211B2 (en) 2007-05-04 2019-05-07 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CA2691434A1 (en) 2007-06-21 2008-12-24 Macrogenics, Inc. Covalent diabodies and uses thereof
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
CN101952312A (en) 2007-07-31 2011-01-19 米迪缪尼有限公司 Multispecific epitope binding proteins and uses thereof
GB0715376D0 (en) * 2007-08-07 2007-09-19 Smith & Nephew Coating
JP5270884B2 (en) * 2007-09-03 2013-08-21 大阪瓦斯株式会社 Polylactic acid-based composite resin particles containing a dispersant and the dispersant
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH &amp; Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2234644B1 (en) * 2008-01-04 2013-07-31 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
JP2011509675A (en) 2008-01-18 2011-03-31 メディミューン,エルエルシー Cysteine ​​engineered antibodies for site-specific conjugation
US20110135571A1 (en) * 2008-02-22 2011-06-09 Wenbin Lin Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
RS54634B1 (en) * 2008-03-17 2016-08-31 Discovery Laboratories, Inc. Ventilation circuit adaptor and proximal aerosol delivery system
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
AR071698A1 (en) 2008-05-09 2010-07-07 Abbott Gmbh & Co Kg Receptor antibodies of advanced glycosylation end products (RAGE) and uses thereof
BRPI0913021A2 (en) * 2008-05-15 2015-10-13 Novartis Ag pulmonary delivery of a fluoroquinolone
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
NZ589436A (en) * 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DK2570147T3 (en) 2008-06-13 2018-01-29 Mannkind Corp Dry powder inhaler and system for drug administration
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2470681C2 (en) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Interactive system and method for real-time force profiling in inhalation
WO2009155450A2 (en) * 2008-06-20 2009-12-23 Board Of Regents, The University Of Texas System Biodegradable photoluminescent polymers
SG192489A1 (en) * 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
JP2011527579A (en) 2008-07-08 2011-11-04 アボット・ラボラトリーズAbbott Laboratories Prostaglandin e2 binding protein and the use
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
TWI614024B (en) 2008-08-11 2018-02-11 Mannkind Corp Use of ultrarapid acting insulin
JP2012500207A (en) * 2008-08-13 2012-01-05 メディバス エルエルシー Aabb- poly (depsipeptide) biodegradable polymers and methods used
JP5722782B2 (en) * 2008-09-26 2015-05-27 ナノバイオ コーポレーション Nanoemulsion therapeutic compositions and methods of use thereof
US8596265B2 (en) 2008-10-22 2013-12-03 Trudell Medical International Modular aerosol delivery system
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
WO2010065882A1 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
SG10201407908VA (en) 2008-12-19 2015-01-29 Macrogenics Inc Covalent diabodies and uses thereof
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
EP2391652A4 (en) * 2009-01-29 2013-01-02 Abbott Lab Il-1 binding proteins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2398461A1 (en) * 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2752648A1 (en) 2009-03-05 2010-09-10 Abbott Laboratories Il-17 binding proteins
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp An apparatus, system and method for measuring resistance in an inhaler
CA2755809C (en) 2009-03-18 2014-02-18 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA2754691A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
DE102009016119A1 (en) * 2009-04-03 2010-10-14 Evonik Degussa Gmbh Dietary supplement containing alpha-keto acids to support diabetes treatment
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
JP2012526726A (en) * 2009-05-15 2012-11-01 株式会社新日本科学 Intranasal pharmaceutical composition for pharmacokinetics was improved
KR20120061040A (en) 2009-05-27 2012-06-12 셀렉타 바이오사이언시즈, 인크. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EP2437767B1 (en) 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
BRPI1013154A2 (en) 2009-06-12 2016-04-05 Mannkind Corp microparticles of diketopiperazine with specific surface areas defined.
SG10201706995VA (en) * 2009-06-12 2017-09-28 Mannkind Corp Diketopiperazine microparticles with defined isomer contents
MX2012000121A (en) 2009-06-22 2012-03-07 Medimmune Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION.
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EA023179B1 (en) * 2009-08-13 2016-05-31 Круселл Холланд Б.В. Antibodies against human respiratory syncytial virus (rsv) and methods of use
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
BR112012004710A2 (en) 2009-09-01 2016-08-16 Abbott Lab Dual variable domain immunoglobulins and use thereof
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
NO2486141T3 (en) 2009-10-07 2018-06-09
JP2013507928A (en) 2009-10-15 2013-03-07 アボット・ラボラトリーズAbbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
US8449916B1 (en) 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
JP5951498B2 (en) 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Monoclonal antibodies to rgma proteins for use in the treatment of retinal nerve fiber layer degeneration
MX348312B (en) 2010-03-02 2017-06-06 Abbvie Inc Therapeutic dll4 binding proteins.
WO2011116090A1 (en) 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
CA2796339A1 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
JP2013527761A (en) 2010-05-06 2013-07-04 ノバルティス アーゲー Therapeutic low density lipoprotein-related protein 6 (LRP6) compositions of multivalent antibodies and methods of use
KR101539683B1 (en) 2010-05-14 2015-07-30 애브비 인코포레이티드 Il-1 binding proteins
WO2011150249A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CA2800206C (en) 2010-06-25 2018-06-05 (Inserm) Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
JP2013537415A (en) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulin and uses thereof
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
AU2011291462A1 (en) 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
EA201300256A1 (en) 2010-08-20 2013-08-30 Новартис Аг Antibodies to epidermal growth factor receptor-3 (her3)
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
MX2013002270A (en) 2010-08-26 2013-05-14 Abbvie Inc Dual variable domain immunoglobulins and uses thereof.
CN103228273B (en) 2010-09-29 2017-04-05 普马特里克斯营业公司 Monovalent metal cations dry inhalation powder
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812417A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2655417A2 (en) 2010-12-21 2013-10-30 AbbVie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
CN103608040B (en) 2011-04-20 2017-03-01 米迪缪尼有限公司 B7-h1 binding antibodies and other molecules of pd-1
CN104080804B (en) 2011-05-21 2017-06-09 宏观基因有限公司 Deimmunized serum binding domain and uses extended serum half-life
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2840270A1 (en) 2011-06-22 2012-12-27 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP6048979B2 (en) 2011-06-23 2016-12-21 ディーエスエム アイピー アセッツ ビー.ブイ. It is used for delivery of biologically active substances, micro or nanoparticles comprising a biodegradable polyester amide copolymers
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP2729180B1 (en) 2011-07-08 2019-01-23 The University of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
TW201323440A (en) 2011-10-24 2013-06-16 Abbvie Inc Immunobinders directed against sclerostin
AU2012345645B2 (en) 2011-12-02 2017-09-07 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (PVL) derived polypeptides
MX2014006735A (en) 2011-12-05 2015-06-04 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3).
EA201491107A1 (en) 2011-12-05 2014-11-28 Новартис Аг Antibodies to epidermal growth factor receptor 3 (her3), aimed at the domain ii her3
EP2791175A2 (en) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2855840A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
JP2015500712A (en) 2011-12-16 2015-01-08 ノバルティス アーゲー Aerosolization device for drug delivery that does not depend on the intake profile
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
UY34558A (en) 2011-12-30 2013-07-31 Abbvie Inc Dual specific binding proteins directed against IL-13 and / or IL-17
DK2807192T3 (en) 2012-01-27 2018-07-23 Abbvie Deutschland A composition and method for the diagnosis and treatment of diseases associated with neuritdegeneration
CA2867649A1 (en) 2012-03-28 2013-10-03 Discovery Laboratories, Inc. Lyophilization of synthetic liposomal pulmonary surfactant
CN104470503A (en) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 Aggregate particles
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256130B2 (en) 2012-05-03 2017-12-21 Johns Hopkins University, The Pharmaceutical nanoparticles showing improved mucosal transport
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
TW201402608A (en) 2012-07-12 2014-01-16 Abbvie Inc IL-1 binding proteins
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
PE11792015A1 (en) 2012-11-01 2015-09-12 Abbvie Inc Dual variable domain immunoglobulins anti-vegf / Dll4 and uses thereof
SG11201503245PA (en) 2012-11-09 2015-05-28 Pfizer Platelet-derived growth factor b specific antibodies and compositions and uses thereof
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US10034988B2 (en) 2012-11-28 2018-07-31 Fontem Holdings I B.V. Methods and devices for compound delivery
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
KR20150100715A (en) 2012-12-21 2015-09-02 앰플리뮨, 인크. Anti-h7cr antibodies
KR20150139830A (en) 2013-02-01 2015-12-14 글리아로직스 인코포레이티드 Compositions and methods for the treatment of neurodegenerative and other diseases
SG10201706468RA (en) 2013-02-08 2017-09-28 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
CA2900652A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2900680A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970947A4 (en) 2013-03-14 2016-10-12 Abbott Lab Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
CN105246916A (en) 2013-03-14 2016-01-13 诺华股份有限公司 Antibodies against notch 3
US9194873B2 (en) 2013-03-14 2015-11-24 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
MX2015013166A (en) 2013-03-15 2015-12-11 Abbvie Inc Dual specific binding proteins directed against il-1 beta and il-17.
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
CA2907566A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
CA2910766A1 (en) 2013-04-30 2014-11-06 Otitopic Inc. Dry powder formulations and methods of use
CN106414489A (en) 2013-05-24 2017-02-15 米迪缪尼有限公司 Anti-b7-h5 antibodies and their uses
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
JP2016522259A (en) 2013-06-19 2016-07-28 インテグレイテッド バイオセラピューティクス,インコーポレイテッド Phenol-soluble modulin, [delta] toxin, toxoid peptides derived from superantigens, and fusions thereof
CA2918369A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
GEP201706794B (en) 2013-08-09 2017-12-11 Macrogenics Inc Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
US10194693B2 (en) 2013-09-20 2019-02-05 Fontem Holdings 1 B.V. Aerosol generating device
WO2015066480A1 (en) 2013-11-01 2015-05-07 Regents Of The University Of Minnesota Protein scaffolds and methods of use
CN108530458A (en) 2013-11-01 2018-09-14 卡拉制药公司 Crystalline forms of therapeutic compounds and uses thereof
TW201524999A (en) 2013-11-13 2015-07-01 Pfizer Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
TW201536320A (en) 2013-12-02 2015-10-01 Abbvie Inc Compositions and methods for treating osteoarthritis
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
US10100115B2 (en) 2014-02-14 2018-10-16 Macrogenics, Inc. Methods for the treatment of vascularizing cancers
JP2017506252A (en) 2014-02-20 2017-03-02 オティトピック インコーポレイテッド Dry powder formulations for inhalation
WO2015127351A1 (en) 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
AU2016227493A1 (en) 2015-03-03 2017-06-08 Kymab Limited Antibodies, uses & methods
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
CN106659800A (en) 2014-03-12 2017-05-10 诺华股份有限公司 Specific sites for modifying antibodies to make immunoconjugates
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625684A (en) 2014-06-26 2016-07-16 Macrogenics Inc Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
US20180193475A1 (en) 2014-08-05 2018-07-12 Novartis Ag Ckit antibody drug conjugates
PE09032017A1 (en) 2014-08-12 2017-07-12 Novartis Ag Drug conjugates with anti-cdh6
US10206871B2 (en) 2014-10-14 2019-02-19 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
AU2015342919A1 (en) 2014-11-07 2017-05-18 Civitas Therapeutics, Inc. Rapamycin powders for pulmonary delivery
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3229803A1 (en) 2014-12-12 2017-10-18 Massachusetts General Hospital Treatment of breast cancer brain metastases
WO2016118921A1 (en) 2015-01-24 2016-07-28 Abbvie, Inc. Compositions and methods for treating psoriatic arthritis
WO2016120828A1 (en) 2015-01-30 2016-08-04 Novartis Ag Treatment of breast cancer by m-csf antagonist
TW201710286A (en) 2015-06-15 2017-03-16 Abbvie Inc Binding proteins against VEGF, PDGF, and/or their receptors
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
US10034857B2 (en) 2015-07-02 2018-07-31 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
KR20180064541A (en) 2015-10-23 2018-06-14 화이자 인코포레이티드 Wherein -il-2 antibodies, and compositions and the use thereof
JP2018534297A (en) 2015-10-29 2018-11-22 ノバルティス アーゲー Antibody conjugate comprising a toll-like receptor agonist
EP3405492A1 (en) 2016-01-21 2018-11-28 Novartis AG Multispecific molecules targeting cll-1
TW201730212A (en) 2016-02-17 2017-09-01 Macrogenics Inc ROR1-binding molecules, and methods of use thereof
AU2017225982A1 (en) 2016-03-02 2018-08-16 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (en) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 Steroid hormone pharmaceutical composition
US20170349653A1 (en) 2016-06-01 2017-12-07 Abbvie Inc. Methods for treating spinal cord injury and pain
US20180008615A1 (en) * 2016-06-03 2018-01-11 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
AU2017281830A1 (en) 2016-06-20 2018-12-13 Kymab Limited Anti-PD-L1 antibodies
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
TW201818933A (en) 2016-10-21 2018-06-01 Glialogix Inc Compositions and methods for the treatment of neurodegenerative and other diseases
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017383458A1 (en) 2016-12-21 2019-06-13 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
WO2018138297A1 (en) 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
WO2018142322A1 (en) 2017-02-03 2018-08-09 Novartis Ag Anti-ccr7 antibody drug conjugates
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2019049862A1 (en) * 2017-09-05 2019-03-14 味の素株式会社 Polylysine derivative
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
CA3025536A1 (en) 2017-12-01 2019-06-01 Pfizer, Inc. Anti-cxcr5 antibodies and compositions and uses thereof

Citations (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2470296A (en) * 1948-04-30 1949-05-17 Abbott Lab Inhalator
US2533065A (en) * 1947-03-08 1950-12-05 George V Taplin Micropulverized therapeutic agents
US2992645A (en) * 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
US3781230A (en) * 1968-12-23 1973-12-25 Champion Int Corp Microcapsular opacifier system
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
US4009280A (en) * 1971-08-10 1977-02-22 Fisons Limited Powder composition for inhalation therapy
US4089800A (en) * 1975-04-04 1978-05-16 Ppg Industries, Inc. Method of preparing microcapsules
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
US4173488A (en) * 1968-12-23 1979-11-06 Champion International Corporation Oil-in-water emulsions containing hydropholeic starch
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4466442A (en) * 1981-10-16 1984-08-21 Schering Aktiengesellschaft Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4524769A (en) * 1981-07-08 1985-06-25 Aktiebolaget Draco Dosage inhalator
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4590206A (en) * 1981-07-24 1986-05-20 Fisons Plc Inhalation pharmaceuticals
US4615697A (en) * 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4679555A (en) * 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4743545A (en) * 1984-08-09 1988-05-10 Torobin Leonard B Hollow porous microspheres containing biocatalyst
US4774958A (en) * 1985-12-05 1988-10-04 Feinstein Steven B Ultrasonic imaging agent and method of preparation
US4789550A (en) * 1984-05-25 1988-12-06 Connaught Laboratories Limited Microcapsule composition suitable for cardiovascular injection
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4847091A (en) * 1985-11-29 1989-07-11 Fisons Plc Pharmaceutical composition including sodium cromoglycate
US4855144A (en) * 1987-10-23 1989-08-08 Advanced Polymer Systems Synthetic melanin aggregates
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4865789A (en) * 1983-11-14 1989-09-12 Akzo Nv Method for making porous structures
US4904479A (en) * 1986-01-17 1990-02-27 Danbiosyst Uk Limited Drug delivery system
US4917119A (en) * 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
US4976968A (en) * 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
US4994281A (en) * 1986-11-12 1991-02-19 Sanraku Incorporated Polylactic acid microspheres and process for producing the same
US5033463A (en) * 1989-10-27 1991-07-23 Miat S.P.A. Multi-dose inhaler for medicaments in powder form
US5064650A (en) * 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5100669A (en) * 1988-02-24 1992-03-31 Biomaterials Universe, Inc. Polylactic acid type microspheres containing physiologically active substance and process for preparing the same
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US5169871A (en) * 1991-12-19 1992-12-08 Hoechst Celanese Corp. Highly porous compressible polymeric powders
US5195520A (en) * 1986-11-05 1993-03-23 Schering Aktiengesellschaft Ultrasonic manometry process in a fluid by means of microbubbles
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5204108A (en) * 1987-10-10 1993-04-20 Danbiosyst Uk Ltd. Transmucosal formulations of low molecular weight peptide drugs
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5306483A (en) * 1989-07-27 1994-04-26 Scientific Development & Research, Inc. Phospholipid delivery system
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5384133A (en) * 1986-08-11 1995-01-24 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
US5393524A (en) * 1991-09-17 1995-02-28 Sonus Pharmaceuticals Inc. Methods for selecting and using gases as ultrasound contrast media
US5407609A (en) * 1989-05-04 1995-04-18 Southern Research Institute Microencapsulation process and products therefrom
US5437873A (en) * 1990-09-21 1995-08-01 Merrell Dow Pharmaceuticals Inc. Superior tasting pharmaceutical composition having porous particles and the process of preparing such pharmaceutical composition
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5482946A (en) * 1989-05-31 1996-01-09 Fisons Plc Medicament inhalation device and formulation
US5518709A (en) * 1991-04-10 1996-05-21 Andaris Limited Preparation of diagnostic agents
US5607695A (en) * 1990-06-06 1997-03-04 Pharmacia & Upjohn Ab Process for the manufacture of porous cellulose matrices
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5795594A (en) * 1993-07-01 1998-08-18 Glaxo Group Limited Salmeterol xinafoate with controlled particle size
US5851453A (en) * 1993-07-01 1998-12-22 University Of Bradford Method and apparatus for the formation of particles
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6063138A (en) * 1994-06-30 2000-05-16 Bradford Particle Design Limited Method and apparatus for the formation of particles
US6372258B1 (en) * 1992-07-08 2002-04-16 Inhale Therapeutic Systems Methods of spray-drying a drug and a hydrophobic amino acid

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU439432B2 (en) * 1968-11-28 1972-08-15
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
SE459005B (en) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett to framstaella sfaeriska polymer particles
ES2032831T5 (en) 1986-08-19 2001-02-16 Genentech Inc Device and dispersion for intrapulmonary delivery of polypeptide growth factors and cytokines.
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
IE61591B1 (en) * 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
AU3073789A (en) * 1988-03-31 1989-10-05 Abbott Laboratories Drug delivery using pulmonary surfactant to facilitate absorption
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE69024363D1 (en) * 1989-10-03 1996-02-01 Advanced Polymer Systems Inc Erodible macroporous hydrogel and their production
WO1991006286A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Method for producing protein microspheres
EP0550436A1 (en) * 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
GB9003821D0 (en) * 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
ES2096653T3 (en) 1990-06-29 1997-03-16 Fisons Plc Pressurized aerosol compositions.
DE69219331T3 (en) * 1991-06-03 2001-06-07 Nycomed Imaging As Improvements in relation to contrast agents
WO1992022288A1 (en) * 1991-06-10 1992-12-23 Schering Corporation Non-chlorofluorocarbon aerosol formulations
DK0592540T3 (en) 1991-07-02 2000-06-26 Inhale Inc Method and device for delivering aerosolized medications
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
DK1086688T3 (en) 1991-12-18 2004-08-16 Minnesota Mining & Mfg Aerosol formulations for suspensions
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
CA2145418A1 (en) * 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
PL176116B1 (en) * 1993-01-25 1999-04-30 Sonus Pharmaceuticals,Inc. Colloidal suspensions able to undergo phase transitions for use as usg contrast media
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4323636A1 (en) * 1993-07-15 1995-01-19 Hoechst Ag Drug preparations of coated, heavy water-soluble drugs for inhalation dosage forms and methods for their preparation
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning Substances
KR960704526A (en) * 1993-09-09 1996-10-09 베. 클로제·우베 하르트만 Active substance and a gas-containing microparticles (Active Principles and Gas Containing Microparticles)
AU679789B2 (en) * 1993-10-01 1997-07-10 Astra Aktiebolag Process I
CZ295827B6 (en) * 1994-03-07 2005-11-16 Nektar Therapeutics Method for aerosolizing a dose of insulin, insulin composition and use thereof
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
AU701440B2 (en) * 1994-09-29 1999-01-28 Quadrant Drug Delivery Limited Spray-dried microparticles as therapeutic vehicles
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
AU6402096A (en) * 1995-06-29 1997-01-30 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery

Patent Citations (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533065A (en) * 1947-03-08 1950-12-05 George V Taplin Micropulverized therapeutic agents
US2470296A (en) * 1948-04-30 1949-05-17 Abbott Lab Inhalator
US2992645A (en) * 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
US4173488A (en) * 1968-12-23 1979-11-06 Champion International Corporation Oil-in-water emulsions containing hydropholeic starch
US3781230A (en) * 1968-12-23 1973-12-25 Champion Int Corp Microcapsular opacifier system
US4009280A (en) * 1971-08-10 1977-02-22 Fisons Limited Powder composition for inhalation therapy
US4089800A (en) * 1975-04-04 1978-05-16 Ppg Industries, Inc. Method of preparing microcapsules
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4524769A (en) * 1981-07-08 1985-06-25 Aktiebolaget Draco Dosage inhalator
US4590206A (en) * 1981-07-24 1986-05-20 Fisons Plc Inhalation pharmaceuticals
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
US4466442A (en) * 1981-10-16 1984-08-21 Schering Aktiengesellschaft Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4615697A (en) * 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4865789A (en) * 1983-11-14 1989-09-12 Akzo Nv Method for making porous structures
US4789550A (en) * 1984-05-25 1988-12-06 Connaught Laboratories Limited Microcapsule composition suitable for cardiovascular injection
US4679555A (en) * 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US4743545A (en) * 1984-08-09 1988-05-10 Torobin Leonard B Hollow porous microspheres containing biocatalyst
US4847091A (en) * 1985-11-29 1989-07-11 Fisons Plc Pharmaceutical composition including sodium cromoglycate
US4774958A (en) * 1985-12-05 1988-10-04 Feinstein Steven B Ultrasonic imaging agent and method of preparation
US4904479A (en) * 1986-01-17 1990-02-27 Danbiosyst Uk Limited Drug delivery system
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US5384133A (en) * 1986-08-11 1995-01-24 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5195520A (en) * 1986-11-05 1993-03-23 Schering Aktiengesellschaft Ultrasonic manometry process in a fluid by means of microbubbles
US4994281A (en) * 1986-11-12 1991-02-19 Sanraku Incorporated Polylactic acid microspheres and process for producing the same
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5204108A (en) * 1987-10-10 1993-04-20 Danbiosyst Uk Ltd. Transmucosal formulations of low molecular weight peptide drugs
US4855144A (en) * 1987-10-23 1989-08-08 Advanced Polymer Systems Synthetic melanin aggregates
US5100669A (en) * 1988-02-24 1992-03-31 Biomaterials Universe, Inc. Polylactic acid type microspheres containing physiologically active substance and process for preparing the same
US5064650A (en) * 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US4917119A (en) * 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
US4976968A (en) * 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
US5407609A (en) * 1989-05-04 1995-04-18 Southern Research Institute Microencapsulation process and products therefrom
US5482946A (en) * 1989-05-31 1996-01-09 Fisons Plc Medicament inhalation device and formulation
US5306483A (en) * 1989-07-27 1994-04-26 Scientific Development & Research, Inc. Phospholipid delivery system
US5033463A (en) * 1989-10-27 1991-07-23 Miat S.P.A. Multi-dose inhaler for medicaments in powder form
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5804212A (en) * 1989-11-04 1998-09-08 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5607695A (en) * 1990-06-06 1997-03-04 Pharmacia & Upjohn Ab Process for the manufacture of porous cellulose matrices
US5437873A (en) * 1990-09-21 1995-08-01 Merrell Dow Pharmaceuticals Inc. Superior tasting pharmaceutical composition having porous particles and the process of preparing such pharmaceutical composition
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5518709A (en) * 1991-04-10 1996-05-21 Andaris Limited Preparation of diagnostic agents
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5393524A (en) * 1991-09-17 1995-02-28 Sonus Pharmaceuticals Inc. Methods for selecting and using gases as ultrasound contrast media
US5169871A (en) * 1991-12-19 1992-12-08 Hoechst Celanese Corp. Highly porous compressible polymeric powders
US6372258B1 (en) * 1992-07-08 2002-04-16 Inhale Therapeutic Systems Methods of spray-drying a drug and a hydrophobic amino acid
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5795594A (en) * 1993-07-01 1998-08-18 Glaxo Group Limited Salmeterol xinafoate with controlled particle size
US5851453A (en) * 1993-07-01 1998-12-22 University Of Bradford Method and apparatus for the formation of particles
US6063138A (en) * 1994-06-30 2000-05-16 Bradford Particle Design Limited Method and apparatus for the formation of particles
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244341A1 (en) * 1997-05-23 2005-11-03 Edwards David A Aerodynamically light particles for pulmonary drug delivery
US7928089B2 (en) 2003-09-15 2011-04-19 Vectura Limited Mucoactive agents for treating a pulmonary disease
US20110217339A1 (en) * 2003-09-15 2011-09-08 Vectura Limited Mucoactive agents for treating a pulmonary disease
US9724664B2 (en) 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
US10300443B2 (en) 2009-03-27 2019-05-28 Bend Research, Inc. Spray-drying process
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9205345B2 (en) 2010-09-03 2015-12-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9358478B2 (en) 2010-09-03 2016-06-07 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus

Also Published As

Publication number Publication date
US20020141947A1 (en) 2002-10-03
ES2175420T3 (en) 2002-11-16
US6399102B1 (en) 2002-06-04
WO1997044013A1 (en) 1997-11-27
US20040047811A1 (en) 2004-03-11
AT215357T (en) 2002-04-15
US6635283B2 (en) 2003-10-21
EP0907356A1 (en) 1999-04-14
JP4315468B2 (en) 2009-08-19
DK907356T3 (en)
JP4489716B2 (en) 2010-06-23
DE69711626T2 (en) 2002-10-24
DE69711626D1 (en) 2002-05-08
CA2255564A1 (en) 1997-11-27
DK0907356T3 (en) 2002-07-29
US6942868B2 (en) 2005-09-13
US5874064A (en) 1999-02-23
JP2006160767A (en) 2006-06-22
JP2000511189A (en) 2000-08-29
US6136295A (en) 2000-10-24
PT907356E (en) 2002-07-31
EP0907356B1 (en) 2002-04-03
CA2255564C (en) 2006-08-29

Similar Documents

Publication Publication Date Title
Pilcer et al. Formulation strategy and use of excipients in pulmonary drug delivery
CA2412561C (en) Highly efficient delivery of a large therapeutic mass aerosol
AU754724B2 (en) Flow resistance modulated aerosolized active agent delivery
DE60026544T2 (en) Use of simple amino acids to the production of porous particles
US8709484B2 (en) Phospholipid-based powders for drug delivery
ES2343124T3 (en) Dry powder compositions with improved dispersibility.
US8137657B2 (en) Carrier particles for use in dry powder inhalers
RU2403059C2 (en) Method of improving pharmaceutical properties of particles, containing diketopiperazine and active agent
Frijlink et al. Dry powder inhalers for pulmonary drug delivery
CA2329875C (en) Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US9439862B2 (en) Phospholipid-based powders for drug delivery
AU2002230993B2 (en) Particles for inhalation having sustained release properties
AU701440B2 (en) Spray-dried microparticles as therapeutic vehicles
AU785288B2 (en) Slow release protein polymers
EP0912166B1 (en) Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US20040185103A1 (en) Methods and compositions for enhanced delivery of bioactive molecules
Rytting et al. Biodegradable polymeric nanocarriers for pulmonary drug delivery
US20030129140A1 (en) Pulmonary delivery of aminoglycosides
US20040105820A1 (en) Phospholipid-based powders for inhalation
Yamamoto et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions
JP6100114B2 (en) Porous microparticles and use
US20030161791A1 (en) Water-soluble polymer conjugates of retinoic acid
US7628977B2 (en) Particles for inhalation having sustained release properties
US20080227690A1 (en) Particles for inhalation having rapid release properties
US5804212A (en) Small particle compositions for intranasal drug delivery

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION